04:41 AM EST, 02/26/2025 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) reported Q4 earnings late Tuesday of $0.27 per diluted share, up from $0.02 a year earlier.

Two analysts polled by FactSet expected breakeven results.

Revenue for the quarter ended Dec. 31 was $174.2 million, compared with $164.3 million a year earlier.

Analysts surveyed by FactSet expected $155.3 million.

The company said it expects 2025 revenue of $600 million to $630 million. Analysts polled by FactSet expect $628.3 million.